{
    "nctId": "NCT00623519",
    "briefTitle": "Assessment of Endometrial Changes in Postmenopausal Women With Breast Cancer in Adjuvant Treatment With Anastrozole",
    "officialTitle": "Assessment of Endometrial Changes in Postmenopausal Women With Breast Cancer in Adjuvant Treatment With Anastrozole.",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 165,
    "primaryOutcomeMeasure": "Global incidence of endometrial changes during the adjuvant treatment with Anastrozole",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Provision of Informed Consent\n* Resectable breast cancer patients, with histological confirmation\n* Patients eligible to receive hormonal adjuvant treatment with Anastrozole\n* They are allowed patients treated with adjuvant chemo or radiotherapy concurrently\n* Patients previously treated with Tamoxifen that had to withdraw treatment due to other reason than endometrial changes are allowed\n* Postmenopausal patients(aged 50 years or over/ without menses in the last months/ FSH level \\>40UI/L / women under 50 years with FSH levels\\>40UI/L).\n* Women showing progesterone and/or estrogen receptors positive.\n\nExclusion Criteria:\n\n* Patients with evidence of metastatic disease\n* Patients unsuitable to receive the medication according the Anastrozole label\n* Patients not giving their Informed Consent",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}